- Home
- YQ vs BOLT Comparison
YQ vs BOLT Comparison
Compare YQ & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- BOLT
- Stock Information
- Founded
- YQ 2012
- BOLT 2015
- Country
- YQ China
- BOLT United States
- Employees
- YQ N/A
- BOLT N/A
- Industry
- YQ Other Consumer Services
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- BOLT Health Care
- Exchange
- YQ Nasdaq
- BOLT Nasdaq
- Market Cap
- YQ 15.7M
- BOLT 16.8M
- IPO Year
- YQ 2020
- BOLT 2021
- Fundamental
- Price
- YQ $1.68
- BOLT $0.40
- Analyst Decision
- YQ
- BOLT Hold
- Analyst Count
- YQ 0
- BOLT 5
- Target Price
- YQ N/A
- BOLT $1.13
- AVG Volume (30 Days)
- YQ 18.3K
- BOLT 146.3K
- Earning Date
- YQ 03-25-2025
- BOLT 05-13-2025
- Dividend Yield
- YQ N/A
- BOLT N/A
- EPS Growth
- YQ N/A
- BOLT N/A
- EPS
- YQ N/A
- BOLT N/A
- Revenue
- YQ $25,922,648.00
- BOLT $7,690,000.00
- Revenue This Year
- YQ N/A
- BOLT N/A
- Revenue Next Year
- YQ N/A
- BOLT $77.45
- P/E Ratio
- YQ N/A
- BOLT N/A
- Revenue Growth
- YQ 10.68
- BOLT N/A
- 52 Week Low
- YQ $1.43
- BOLT $0.38
- 52 Week High
- YQ $3.19
- BOLT $1.48
- Technical
- Relative Strength Index (RSI)
- YQ 43.31
- BOLT 38.73
- Support Level
- YQ $1.43
- BOLT $0.38
- Resistance Level
- YQ $1.94
- BOLT $0.47
- Average True Range (ATR)
- YQ 0.22
- BOLT 0.04
- MACD
- YQ -0.04
- BOLT -0.00
- Stochastic Oscillator
- YQ 20.46
- BOLT 11.49
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.